Skip to content

Clinical Study Of Naga Bhasma in the Madhumehi (Diabetic) Patients

Pharmaceutical development of Trinshati and Shashti Puti Naga Bhasma and their comparative clinical efficacy in the management of Madhumeha (Type 2 Diabetes)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/05/008451
Enrollment
120
Registered
2017-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having chief and associated complains of Madhumeha (Prabhuta Avilamutrata pipashadhikya kshudhadhikya etc) Known patient of Type 2 Diabetes Mellitus. Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Naga Bhasma 30 puta: One group of patients will be treated with 30 Puta Naga Bhasma 62.5 mg and Nisha 62.5 mg with Amalaki Churna 62.5 mg BD Anupana with Honey for 90 days. Intervention

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients having chief & associated complains of Madhumeha (Prabhuta-Avilamutrata, pipashadhikya, kshudhadhikya etc.) 2) Known patient of Type 2 Diabetes Mellitus and aslo the preliminarily diagnosed patients on the basis of signs and symptoms of the disease are confiremed by FBS and PPBS.

Exclusion criteria

Exclusion criteria: 1) Age more than 60 and below 30 years 2) All patients of diabetes mellitus receiving insulin. 3) Malignanat and accelerated hypertensive. 4) CVS disorders (CAD) 5) CNS disorder e.g. encephalopathy 6) HIV positive cases. 7) Other chronic debilitating diseases like STD etc. • Pregnant woman and planning to be pregnant within six month • Lactating mothers. • Secondary Diabetes mellitus

Design outcomes

Primary

MeasureTime frame
The primary end-point was symptomatic relief, reduction and control of NIDDM symptoms, polydipsia, polyuria, polyphagia, burning sensation in hands and soles, pain/ cramps, fasting and postprandial blood sugar levels.Timepoint: After 3 months trial drugs intervention.

Secondary

MeasureTime frame
Naga Bhasma safety and toxicity profiles were secondary end points.Timepoint: 18 months

Countries

India

Contacts

Public ContactProf B J Patgiri

Institute for Post Graduate Teaching and Research in Ayurveda

patgiri124@gmail.com9426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026